Eisai Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ESAIY research report →
About the company
Eisai Co. , Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan.
- CEO
- Haruo Naito
- IPO
- 2023
- Employees
- 11,067
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $7.32B
- P/E
- 31.12
- P/S
- 1.45
- P/B
- 1.33
- EV/EBITDA
- 11.90
- Div Yield
- 3.76%
- Gross Margin
- 76.83%
- Op Margin
- 4.87%
- Net Margin
- 4.67%
- ROE
- 4.44%
- ROIC
- 2.75%
- Revenue
- $875.15B · 10.86%
- Net Income
- $40.88B · -11.95%
- EPS
- $36.75 · -10.23%
- Op Income
- $42.63B
- FCF YoY
- 581.81%
- 52W High
- $9.22
- 52W Low
- $5.69
- 50D MA
- $6.57
- 200D MA
- $7.37
- Beta
- -0.07
- Avg Volume
- 209.39K
Get TickerSpark's AI analysis on ESAIY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ESAIY coverage
Recent articles, reports, and earnings notes.
No research on ESAIY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ESAIY report →Similar companies
Peers in the same neighborhood.